THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE
The prevalence of congestive heart failure (CHF) is growing further with age, and 65% of the sufferers are in the age group from 65 to 80 y.o. Despite success in CHF treatment, mean year mortality is about 6%, and mortality of those with clinically salient CHF reaches 12%. To increase duration of li...
Saved in:
| Main Author: | A. B. Khadzegova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2014-09-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01) -
RATIONAL CHOICE OF Β-ADRENOBLOCKERS IN CHRONIC HEART FAILURE THERAPY
by: M. L. Maximov
Published: (2015-12-01) -
URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
by: M. P. Savenkov, et al.
Published: (2016-01-01) -
CHRONIC HEART FAILURE OF ISCHEMIC GENESIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: POSSIBILITIES OF COMBINATION THERAPY INCLUDING NEBIVOLOL
by: P. A. Fedotov, et al.
Published: (2014-07-01) -
Pleiotropic activity of antihypertensives in atherothrombogenesis. Nebivolol: increasing possibilities and reducing restrictions
by: M. G. Bubnova
Published: (2008-12-01)